{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "1",
        "name": "Amendment 1",
        "scope": {
          "id": "6e9530ae-e288-4c84-835d-d5ecce11aec1",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "e2c45bae-133e-4e67-a90a-f135badcc6dd",
          "code": {
            "id": "b3f4ec55-879b-4a84-88a9-9bf114d7ac1a",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "26048407-ff20-426c-8c23-5ab6646aa3ee",
            "type": {
              "id": "a7599184-a203-428b-8ed9-6b2cb30629f2",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Amendment 1 to the protocol",
        "effectiveDate": "2014-06-12",
        "previousVersion": "Original",
        "newVersion": "1"
      },
      {
        "id": "amend_2",
        "number": "2",
        "name": "Amendment 2",
        "scope": {
          "id": "5c69bac5-d72b-47e0-955c-8f742fcd5c21",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "30d23b94-0d2e-4b35-8567-cb8d21601a75",
          "code": {
            "id": "36648058-6d99-48f3-80c6-81b0ed1f1d6b",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "237bb054-e0e8-47ef-b95c-ce5283f1e088",
            "type": {
              "id": "56796dff-e6b2-4576-b5f5-8ea68c356439",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Amendment 2 to the protocol",
        "effectiveDate": "2015-02-11",
        "previousVersion": "1",
        "newVersion": "2"
      },
      {
        "id": "amend_3",
        "number": "3",
        "name": "Amendment 3",
        "scope": {
          "id": "d46e985b-0f45-492a-bfbf-15d15490dece",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "7df7a15f-8146-4d1e-9196-986d5f91025a",
          "code": {
            "id": "c7816060-d8fd-4430-afd2-880f8b20a3f4",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "e145b037-ab06-4184-8727-990b034811da",
            "type": {
              "id": "0191bd07-d821-4c5c-9b1a-ce81627dfe8c",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Amendment 3 to the protocol",
        "effectiveDate": "2016-06-17",
        "previousVersion": "2",
        "newVersion": "3"
      },
      {
        "id": "amend_4",
        "number": "4",
        "name": "Amendment 4",
        "scope": {
          "id": "d20b6cc1-cc9c-411b-ac63-df979bcacd88",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "ec7bbef5-a764-4c1f-b3f1-d21b8cfc23a3",
          "code": {
            "id": "7b32e899-4cc8-43a0-a655-84f5b4bfe8fc",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "02813392-b660-4782-bb5c-f82080830d31",
            "type": {
              "id": "a87a2c2b-c0af-4528-9a4a-ca9aa6ca4085",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The purpose of this amendment is to add benefits and risks evaluation information and updated study procedures in the context of the ongoing COVID-19 pandemic; introduce the option of off-site phone visits every other cycle for subjects who have been receiving single-agent veliparib/placebo at a stable dose; remove references to Blinded/Unblinded TA MD and study teams as the sponsor was unblinded at the time of the primary analysis; include language to indicate that AbbVie may remove requirements for central laboratory and radiology scans; update tumor assessment schedule from every 9 weeks to allow every 12 weeks; update IDMC review language; update guidelines on when chemotherapy can begin based on hematologic blood counts; add language on the reporting of myelodysplastic syndrome or acute myeloid leukemia; modify the Table of Study Procedures for Post Treatment Phase; clarify the timing of additional OS analyses; and change duration of response from secondary to tertiary endpoint.",
        "effectiveDate": "2020-07-23",
        "reasonIds": [
          "ar_4_1",
          "ar_4_2",
          "ar_4_3",
          "ar_4_4",
          "ar_4_5"
        ],
        "previousVersion": "3",
        "newVersion": "4"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_4_1",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_2",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_3",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_4",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_5",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [
      {
        "id": "country_1",
        "name": "United States",
        "instanceType": "Country",
        "code": "US"
      },
      {
        "id": "country_2",
        "name": "Australia",
        "instanceType": "Country",
        "code": "AU"
      }
    ],
    "studySites": [],
    "summary": {
      "amendmentCount": 4,
      "countryCount": 2,
      "siteCount": 0
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "Global",
      "instanceType": "GeographicScope",
      "countryIds": [
        "country_1",
        "country_2"
      ],
      "regions": [
        "North America",
        "Australia",
        "Northern Europe",
        "Western Europe",
        "Eastern Europe",
        "European Union"
      ]
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "1",
        "effectiveDate": "2014-06-12",
        "summary": null,
        "previousVersion": "Original",
        "newVersion": "1",
        "reasons": []
      },
      {
        "number": "2",
        "effectiveDate": "2015-02-11",
        "summary": null,
        "previousVersion": "1",
        "newVersion": "2",
        "reasons": []
      },
      {
        "number": "3",
        "effectiveDate": "2016-06-17",
        "summary": null,
        "previousVersion": "2",
        "newVersion": "3",
        "reasons": []
      },
      {
        "number": "4",
        "effectiveDate": "2020-07-23",
        "summary": "The purpose of this amendment is to add benefits and risks evaluation information and updated study procedures in the context of the ongoing COVID-19 pandemic; introduce the option of off-site phone visits every other cycle for subjects who have been receiving single-agent veliparib/placebo at a stable dose; remove references to Blinded/Unblinded TA MD and study teams as the sponsor was unblinded at the time of the primary analysis; include language to indicate that AbbVie may remove requirements for central laboratory and radiology scans; update tumor assessment schedule from every 9 weeks to allow every 12 weeks; update IDMC review language; update guidelines on when chemotherapy can begin based on hematologic blood counts; add language on the reporting of myelodysplastic syndrome or acute myeloid leukemia; modify the Table of Study Procedures for Post Treatment Phase; clarify the timing of additional OS analyses; and change duration of response from secondary to tertiary endpoint.",
        "previousVersion": "3",
        "newVersion": "4",
        "reasons": [
          "Safety",
          "Regulatory",
          "Operational",
          "Scientific",
          "Administrative"
        ]
      }
    ],
    "geographicScope": {
      "type": "Global",
      "countries": [
        {
          "name": "United States",
          "code": "US"
        },
        {
          "name": "Australia",
          "code": "AU"
        }
      ],
      "regions": [
        "North America",
        "Australia",
        "Northern Europe",
        "Western Europe",
        "Eastern Europe",
        "European Union"
      ],
      "plannedSites": 200
    },
    "sites": []
  }
}